Biomaterial-engineered intra-articular drug delivery systems for osteoarthritis therapy
Biomaterial-engineered intra-articular drug delivery systems for osteoarthritis therapy
复制标题
DOI：
10.1080/10717544.2019.1660434
复制
发表时间：
2019-01-01
期刊：
影响因子：
6
通讯作者：
Chen, Ruijie
中科院分区：
文献类型：
--
作者：
Kou, Longfa;Xiao, Shuyi;Chen, Ruijie
Osteoarthritis (OA) is a progressive and degenerative disease, which is no longer confined to the elderly. So far, current treatments are limited to symptom relief, and no valid OA disease-modifying drugs are available. Additionally, OA relative joint is challenging for drug delivery, since the drugs experience rapid clearance in joint, showing a poor bioavailability. Existing therapeutic drugs, like non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, are not conducive for long-term use due to adverse effects. Though supplementations, including chondroitin sulfate and glucosamine, have shown beneficial effects on joint tissues in OA, their therapeutic use is still debatable. New emerging agents, like Kartogenin (KGN) and Interleukin-1 receptor antagonist (IL-1 ra), without a proper formulation, still will not work. Therefore, it is urgent to establish a suitable and efficient drug delivery system for OA therapy. In this review, we pay attention to various types of drug delivery systems and potential therapeutic drugs that may escalate OA treatments.
